ReviewCell reports. Medicine2021

The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC).

Ravi Salgia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.